




<b>(51) 国際特許分類6</b> <b>C07D 473/34, 473/30, A61K 31/52</b>	<b>A1</b>	<b>(11) 国際公開番号</b> <b>WO98/01448</b>  <b>(43) 国際公開日</b> 1998年1月15日(15.01.98)
<b>(21) 国際出願番号</b> PCT/JP97/02310  <b>(22) 国際出願日</b> 1997年7月3日(03.07.97)  <b>(30) 優先権データ</b> 特願平8/173857      1996年7月3日(03.07.96)      JP  <b>(71) 出願人</b> (米国を除くすべての指定国について) 株式会社 ジャパンエナジー (JAPAN ENERGY CORPORATION)[JP/JP] 〒105 東京都港区虎ノ門二丁目10番1号 Tokyo, (JP) <b>(72) 発明者; および</b> <b>(75) 発明者/出願人</b> (米国についてのみ) 廣田耕作(HIROTA, Kōsaku)[JP/JP] 〒502 岐阜県岐阜市三田洞東三丁目22-5号 Gifu, (JP) 磯部義明(ISOBE, Yoshiaki)[JP/JP] 知場伸介(CHIBA, Nobuyoshi)[JP/JP] 高久春雄(TAKAKU, Haruo)[JP/JP] 松井広行(MATSUI, Hiroyuki)[JP/JP] 荻田晴久(OGITA, Haruhisa)[JP/JP] 〒335 埼玉県戸田市新曽南三丁目17番35号 株式会社 ジャパンエナジー内 Saitama, (JP)		<b>(74) 代理人</b> 弁理士 平木祐輔, 外(HIRAKI, Yusuke et al.) 〒105 東京都港区虎ノ門一丁目17番1号 虎ノ門5森ビル3F Tokyo, (JP)  <b>(81) 指定国</b> AU, CA, JP, KR, NO, NZ, US, 欧州特許 (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  添付公開書類 国際調査報告書
<b>(54) Title: NOVEL PURINE DERIVATIVES</b>  <b>(54) 発明の名称</b> 新規プリン誘導体  <b>(57) Abstract</b> Purine derivatives represented by general formula (I), their tautomers or pharmaceutically acceptable salts thereof, and interferon secretion inducers, antiviral agents and anticancer drugs containing the same. In said formula (I) R <sup>2</sup> represents hydrogen or hydrocarbyl (wherein -CH <sub>2</sub> - not directly bonded to the purine skeleton and CH <sub>2</sub> in -CH <sub>3</sub> not directly bonded to the purine skeleton may be replaced by carbonyl, sulfonyl, -O- or -S-; =CH <sub>2</sub> may be replaced by =O or =S; and C-H in -CH <sub>2</sub> not directly bonded to the purine skeleton, C-H in -CH <sub>3</sub> not directly bonded to the purine skeleton, C-H in >CH not directly bonded to the purine skeleton, C-H in =CH- not directly bonded to the purine skeleton and C-H in =CH <sub>2</sub> may be replaced by N, C-halogeno or C-CN); R <sup>6</sup> represents hydroxy or amino optionally substituted by one or two hydrocarbon groups; R <sup>8</sup> represents hydroxy, mercaptor, acyloxy or oxycarbonyl substituted by hydrocarbyl; and R <sup>9</sup> represents hydrocarbyl (wherein -CH <sub>2</sub> - not directly bonded to the purine skeleton and CH <sub>2</sub> in -CH <sub>3</sub> not directly bonded to the purine skeleton may be replaced by carbonyl, sulfonyl, -O- or -S-; =CH <sub>2</sub> may be replaced by =O or =S; and C-H in -CH <sub>2</sub> not directly bonded to the purine skeleton, C-H in -CH <sub>3</sub> not directly bonded to the purine skeleton, C-H in >CH not directly bonded to the purine skeleton, C-H in =CH- not directly bonded to the purine skeleton, C-H in =CH <sub>2</sub> and C-H in =CH may be replaced by N, C-halogeno or C-CN).		



(I)